Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method
- PMID: 7450906
Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method
Abstract
Our previous findings that antigens, such as ovalbumin (OA) and the extract of ragweed pollen (RAG), could be rendered nonantigenic, nonallergenic and tolerogenic by conjugation with polyethylene glycol (PEG) have been extended in the present study to the synthesis of conjugates of a variety of antigens with monofunctional monomethoxy-PEGs (mPEGS) of different molecular weights by the use of the mixed anhydride method. Thus, mPEGs with molecular weights of 2,000, 5,000, 10,000 and 20,000 were coupled to proteins such as dog serum albumin (DA), bovine pancreatic ribonuclease, OA and the constituents of pollen, helminth and bacterial allergens (RAG, Timothy grass pollen, Ascaris suum and Micropolyspora faeni). All these mPEG conjugates depressed markedly the ongoing IgE antibody formation in sensitized animals, in spite of additional injections of the sensitizing dose of the appropriate antigen. Moreover, the allergenicity of the proteins was either totally abolished or markedly reduced after coupling to mPEGs. Conjugates of DA and OA of varying degree of substitution (i.e. number of mPEG molecules attached per protein molecule) were prepared with mPEGs of different molecular weights and their immunological properties were assessed. It appears that, for a series of tolerogenic conjugates of the same antigen, there exists some inverse relationship between the degree of substitution and the molecular weight of mPEG, i.e. a high level of tolerogenicity with a concomitant reduction or total loss of allergenicity was achieved with a lower degree of substitution utilizing mPEGs of increasing molecular weights. On the basis of these results, it is concluded that a variety of allergens may be converted by conjugation with mPEGs to tolerogenic products with a potential for use in the therapy of patients allergic to a wide spectrum of common allergens.
Similar articles
-
Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin.Int Arch Allergy Appl Immunol. 1981;64(1):100-14. Int Arch Allergy Appl Immunol. 1981. PMID: 6450171
-
Suppression of reaginic antibody formation. III. Relationship between immunogenecity and tolerogenicity of hapten-carrier conjugates.J Immunol. 1976 Jun;116(6):1711-8. J Immunol. 1976. PMID: 58048
-
Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol.Int Arch Allergy Appl Immunol. 1978;56(2):159-70. doi: 10.1159/000232019. Int Arch Allergy Appl Immunol. 1978. PMID: 74362
-
Immunotherapy with monomethoxypolyethylene glycol modified allergens.Crit Rev Ther Drug Carrier Syst. 1990;6(4):315-65. Crit Rev Ther Drug Carrier Syst. 1990. PMID: 2186872 Review.
-
Carl Prausnitz Memorial Lecture. Suppression of antibody responses by chemically modified antigens.Int Arch Allergy Appl Immunol. 1991;94(1-4):11-20. Int Arch Allergy Appl Immunol. 1991. PMID: 1937863 Review.
Cited by
-
Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide.Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5852-6. doi: 10.1073/pnas.89.13.5852. Proc Natl Acad Sci U S A. 1992. PMID: 1378618 Free PMC article.
-
Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates of peptides.J Protein Chem. 1991 Dec;10(6):623-7. doi: 10.1007/BF01025714. J Protein Chem. 1991. PMID: 1726134
-
Polymer conjugates. Pharmacokinetic considerations for design and development.Clin Pharmacokinet. 1994 Oct;27(4):290-306. doi: 10.2165/00003088-199427040-00004. Clin Pharmacokinet. 1994. PMID: 7834965 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources